IRIS
MASSIMINO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.957
EU - Europa 1.979
AS - Asia 1.437
SA - Sud America 421
AF - Africa 338
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.136
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.855
IT - Italia 825
SG - Singapore 689
CN - Cina 423
BR - Brasile 387
IE - Irlanda 334
CI - Costa d'Avorio 229
UA - Ucraina 218
DE - Germania 136
IN - India 131
BE - Belgio 97
CA - Canada 94
NL - Olanda 81
SN - Senegal 75
RU - Federazione Russa 69
GB - Regno Unito 50
VN - Vietnam 49
FI - Finlandia 42
KR - Corea 36
SE - Svezia 25
BD - Bangladesh 20
FR - Francia 18
PL - Polonia 16
UZ - Uzbekistan 15
AR - Argentina 14
CZ - Repubblica Ceca 13
CH - Svizzera 12
NG - Nigeria 12
GR - Grecia 11
HK - Hong Kong 11
JP - Giappone 10
TR - Turchia 10
IQ - Iraq 8
MA - Marocco 7
EC - Ecuador 6
ES - Italia 6
IL - Israele 6
IR - Iran 6
TN - Tunisia 6
AT - Austria 5
BG - Bulgaria 5
MX - Messico 5
CO - Colombia 4
NO - Norvegia 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
ID - Indonesia 3
KE - Kenya 3
LB - Libano 3
PE - Perù 3
RS - Serbia 3
SA - Arabia Saudita 3
VE - Venezuela 3
AU - Australia 2
EG - Egitto 2
HU - Ungheria 2
KZ - Kazakistan 2
PK - Pakistan 2
PY - Paraguay 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
IS - Islanda 1
JO - Giordania 1
LT - Lituania 1
NA - Namibia 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TH - Thailandia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.136
Salva come PNG Salva come JPEG
Città #
Santa Clara 727
Dallas 701
Chandler 443
Singapore 432
Dublin 334
Chicago 283
Catania 230
Abidjan 229
Jacksonville 219
Ashburn 128
Boardman 125
Kochi 104
Cambridge 93
Lawrence 91
Andover 87
Nanjing 82
Dakar 74
Grafing 64
Hefei 64
Beijing 62
Toronto 60
Civitanova Marche 59
Los Angeles 57
Rotterdam 55
Wingene 50
Des Moines 48
Wilmington 44
San Mateo 43
Palermo 39
New York 36
Seoul 35
Milan 30
Munich 30
Dong Ket 27
São Paulo 27
Brussels 24
The Dalles 23
Turku 22
Columbus 21
Ottawa 19
Rome 19
Council Bluffs 17
Hebei 17
Nanchang 17
Shenyang 17
Jiaxing 16
Seattle 16
Falls Church 15
Hanoi 15
Saint Petersburg 15
Bari 14
Messina 14
Rio de Janeiro 14
Aci Catena 13
Belo Horizonte 13
Changsha 13
Abuja 12
Bremen 12
Santa Venerina 12
Brasília 11
Brno 11
Lappeenranta 11
Nijmegen 11
Tokyo 10
Helsinki 9
Izegem 9
Montreal 9
Pune 9
Tianjin 9
Warsaw 9
Brooklyn 8
Curitiba 8
Dhaka 8
Hong Kong 8
Redmond 8
Reggio Emilia 8
San Francisco 8
San Giovanni la Punta 8
Boston 7
London 7
Mascalucia 7
Phoenix 7
Washington 7
Acireale 6
Bernareggio 6
Leawood 6
Manaus 6
Moscow 6
Paternò 6
Portland 6
Tashkent 6
Verona 6
Fantina 5
Frankfurt am Main 5
Giardini-Naxos 5
Guangzhou 5
Hanover 5
Manchester 5
Mazzarino 5
Milazzo 5
Totale 5.903
Salva come PNG Salva come JPEG
Nome #
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 213
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 182
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 174
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 127
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 121
Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series 120
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 120
A novel and selective sigma-1/2 receptor ligand (PO680C): Binding properties and expression of tissue transglutaminase 120
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 120
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 119
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 118
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 117
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 115
A novel and selective σ1/2 receptor ligand (PO680C): binding properties and expression of tissue transglutaminase 112
Comparative proteomic analysis of insulin receptor isoform A and B signaling 107
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 107
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 103
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 103
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 100
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 100
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 99
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 99
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 99
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 99
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 96
New insights in thyroid cancer and p53 family proteins 95
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 95
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 94
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 93
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 93
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 92
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 91
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 91
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 90
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 90
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 89
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 88
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 87
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 87
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 87
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 86
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 85
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 84
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 84
Opportunities and challenges of liquid biopsy in thyroid cancer 83
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 82
Uncommon long-term survival in a patient with chronic myeloid leukemia 82
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 82
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 81
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 80
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 80
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 79
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 77
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 75
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 75
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 72
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series 72
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 71
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 70
UNFAVOURABLE OUTCOME OF CML PATIENTS CARRYING COMPLEX VARIANT CHROMOSOMAL TRANSLOCATIONS TREATED WITH TYROSINE KINASE INHIBITORS 70
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 70
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 70
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 69
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 69
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 69
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 69
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 68
Ruolo delle IAPs e di Smac/DIABLO nella resistenza ai farmaci antiblastici di cellule di carcinoma indifferenziato della tiroide 68
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy 66
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 65
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 65
High BCR-ABL expression levels at diagnosis may predict unfavorable CML responses to Imatinib therapy 63
SYNTHESIS OF BNIT AN ISOTHIOCYANATE DERIVATIVE OF N-BENZYL-NORMETAZOCINE AS ACYLANT AGENT FOR σ1 RECEPTOR 61
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 60
Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report 59
Experimental and Computational Characterization of Amino Acidic Residues in the BCR-ABL kinase domain contributing to TKI resistance in patients with Chronic Myeloid Leukemia 58
EFFICACY OF IMATINIB MESYLATE ON CHRONIC PHASE CML PATIENTS ACCRUED IN THE SCREEN MULTICENTER STUDY: INTERIM REPORT ON THE FIRST 193 CASES 58
L’attività tirosin-chinasica di BCR/Abl modula l’espressione di IRF-5 58
HIGH BCR-ABL LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH UNFAVORABLE RESPONS- ES TO IMATINIB 58
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 58
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 57
Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines 57
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 55
Computational and biological characterization of nuclear import/export signals of the human BCR protein 55
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 55
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 55
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 55
High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib 54
THE SCREEN PROJECT: A CML DATA REGISTRY IN SICILY AND CALABRIA 54
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 53
REThinking the role of the RET oncogene in breast cancer 52
IRF5 promotes the proliferation of human thyroid cancer cells. 52
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 50
Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor 49
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib 49
SINTESI E VALUTAZIONE FARMACOLOGICA DI DERIVATI METIL 2-[(4-BENZILPIPERIDIN-1-IL)METIL]-1-FENIL-CICLOPROPANCARBOSSILATO COME LIGANDI SIGMA AD ALTA AFFINITÀ 49
RAPID RESPONSE TO DASATINIB IN A CML BLAST CRISIS PATIENT THAT SUBSEQUENTLY DEVELOPED SEQUENTIAL BCR-ABL MUTATIONS CAUSING MULTI-DRUG RESISTANCE: A CASE REPORT 48
Molecular dynamics simulations reveal the role of five BCR-ABL kinase domain critical residues in TKIS binding 44
HIGH DOSE IMATINIB TO ACHIEVE MOLECULAR RESPONSES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN LATE CHRONIC PHASE AND COMPLETE CYTOGENETIC RESPONSE: IS IT WORTHWHILE? 39
Computational and Experimental Characterization of Critical Amino Acid Residues in the BCR-ABL Kinase Domain Explaining Imatinib Resistance in Patients with Chronic Myeloid Leukemia 38
Totale 8.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.568
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.568
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021435 0 0 0 11 128 16 51 3 106 4 68 48
2021/2022686 54 97 15 9 112 13 103 27 52 14 35 155
2022/20231.373 106 102 43 153 91 214 19 263 289 11 50 32
2023/2024766 57 107 30 36 32 184 11 44 7 35 133 90
2024/20252.956 111 445 116 175 585 394 191 80 187 203 315 154
2025/20261.401 300 272 790 39 0 0 0 0 0 0 0 0
Totale 8.330